Nxera
NXERA CONTEMPLATIVE RIBBONS 2 8 K

Our Pipeline

We have a broad pipeline of novel drugs that have potential to become first-in-class or best-in-class medicines for a range of diseases.

We are developing molecules both in-house and with partners to ensure that our medicines have the best chances of reaching patients in need.

In-house Programs

Our emerging pipeline of in-house programs comprise multiple drug candidates that address patient populations across our key focus areas of neurology, GI and immunology, metabolic disorders and rare diseases.

Daridorexant

Filing

Indication

Insomnia

Modality

Small molecule

GPR52 agonist

Phase 1

Indication

Schizophrenia

Modality

Small molecule

Candidate

NXE0048149

EP4 antagonist

Cancer research

Phase 1

Indication

Immuno-oncology

Modality

Small molecule

Candidate

NXE0039732

Partner

Cancer Research UK

EP4 agonist

Phase 1

Indication

Inflammatory Bowel Disease

Modality

Small molecule

Candidate

NXE0033744

Muscarinic M1-preferring agonist (Japan)

Preclinical

Indication

Neurology

Modality

Small molecule

Candidate

NBI-1117567

GPR35 agonist

Preclinical

Indication

Inflammatory bowel disease/GI disorders

Modality

Small molecule

Candidate

NXE0027477